Clinical Trials Logo

VHL Gene Inactivation clinical trials

View clinical trials related to VHL Gene Inactivation.

Filter by:
  • None
  • Page 1

NCT ID: NCT03401788 Active, not recruiting - VHL Syndrome Clinical Trials

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Start date: May 2, 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.

NCT ID: NCT03108066 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma

Start date: April 24, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL patients treated with PT2385.